Abstract-Our previous studies have demonstrated that the introduction of angiotensin II type I receptor antisense (AT 1 R-AS) cDNA by a retrovirally mediated delivery system prevents the development of hypertension in the spontaneously hypertensive rat (SHR), an animal model for primary hypertension in humans. These results have led us to propose the hypothesis that an interruption of the renin-angiotensin system (RAS) activity at a genetic level would prevent hypertension on a permanent basis. F 1 and F 2 generations of offspring from a retroviral vector, LNSV-and LNSV-AT 1 R-AS-treated SHR, were generated, and various physiological parameters indicative of hypertension were studied and compared with those of their parents to investigate this hypothesis. Both F 1 and F 2 generations of LNSV-AT 1 R-AS-treated SHR expressed a persistently lower blood pressure, decreased cardiac hypertrophy and fibrosis, decreased medial thickness, and normalization of renal artery excitation-contraction coupling, Ca 2ϩ current, and [Ca 2ϩ ] i when compared with offspring derived from the LNSV-treated SHR. In fact, the magnitude of the prevention of these pathophysiological alterations was similar to that observed in the LNSV-AT 1 R-AS-treated SHR parent. The prevention of cardiovascular pathophysiology and expression of normotensive phenotypes are, at least in part, a result of integration and subsequent transmission of AT 1 R-AS from the SHR parents to offspring. These data demonstrate that a single intracardiac injection of LNSV-AT 1 R-AS causes a permanent cardiovascular protection against hypertension as a result of a genomic integration and germ line transmission of the AT 1 R-AS in the SHR offspring. The full text of this article is available at http://www.circresaha.org. (Circ Res. 1999;85:e44 -e50.) Key Words: AT 1 receptor antisense Ⅲ gene therapy Ⅲ hypertension Ⅲ SHR Ⅲ antisense transmission to offspring H ypertension is a complex disease that is associated with major economic and emotional burdens to society. It is also a significant risk factor in stroke, arteriosclerosis, heart failure, coronary artery disease, and progressive renal damage. 1,2 Decades of investigation have established that a hyperactive renin-angiotensin system (RAS) is one of the many physiological events that becomes dysfunctional in hypertension. [2] [3] [4] [5] This fact is further supported by the observation that pharmacological interruption in the activity of the RAS has proved to be highly successful in the treatment and management of hypertension in a significant population of hypertensive patients. 6, 7 In spite of this success, the traditional pharmacological therapy targeted to inhibit specific components of the RAS suffers from many significant disadvantages. One is patient compliance. This is particularly important in view of the fact that chronic administration of drugs is almost always necessary for a persistent, long-term antihypertensive effect, and prolonged therapy with certain antihypertensive agents can lead to significant side effects such as coughing, angioedema, hypotension, renal dysfunction, and hyperkalemia. 8 -10 Additionally, although a traditional pharmacological strategy can be successful in the control and the management of high blood pressure (BP), its effectiveness in the prevention and/or reversal of other associated pathophysiological alterations such as tissue remodeling leading to end-organ damage remains to be proven. 11 In fact, disproportionate reversal of some alterations, such as left ventricular hypertrophy and peripheral resistance, has proven to be unfavorable in the successful management of this disease. 12, 13 In view of the success of pharmacological agents targeted toward the inhibition of the RAS, and the recent rapid advances in gene delivery, we decided to investigate whether antisense gene therapy could be a superior treatment for hypertension. We used a retrovirally mediated delivery system to administer AT 1 receptor antisense (AT 1 R-AS) cDNA
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Materials and Methods

Preparation of Viral Particles
Containing AT 1 R-AS AT 1 R-AS was cloned in a retroviral vector containing long terminal repeats, neomycin selection, and simian virus promoter (LNSV) as described previously. 14, 15, 19 Media-containing viral particles from the PA317 cells were collected and concentrated to provide 1ϫ10 9 to 2ϫ10 10 cfu/mL as described previously. 19 Viral particles that did not contain AT 1 R-AS (LNSV) were also prepared by the same protocol and used in control experiments.
Administration of LNSV-and LNSV-AT 1 R-AS-Containing Viral Particles in Rats
Five-day-old Wistar Kyoto (WKY) and spontaneously hypertensive (SHR) rats were divided into two groups: virus-along control (LNSV) or virus-containing AT 1 R-AS (LNSV-AT 1 R-AS). Animals were injected with a bolus of 1ϫ10 10 cfu of viral particles in 10 L physiological saline intracardially, weaned, and raised as described previously. 16 -18 Indirect BP was monitored throughout development. Two sets of parents of LNSV-or LNSV-AT 1 R-AS-treated WKY and SHR were bred at 100 days of age to generate F 1 offspring. Similar to their parents, they were weaned, raised, and monitored for BP indirectly by the tail-cuff method. 16 -18 At 100 days of age, two sets of F 1 offspring of LNSV-and LNSV-AT 1 R-AS-treated WKY and SHR were bred to generate F 2 offspring. One hundred-day-old parents and F 1 and F 2 offspring were used for all biochemical and physiological experiments.
Biochemical Experiments
Binding of 125 I-Sar 1 1le 8 -Ang II to membrane AT 1 receptors was carried out as described elsewhere. 14, 15 Computer-assisted Scatchard analysis was done to determine the B max and K d values. Polymerase chain reaction (PCR) followed by a Southern analysis was carried out to determine the genomic integration of the AT 1 R-AS essentially as described elsewhere. 20 -22 The expression of AT 1 R-AS transcript in various Ang II target tissues was carried out by a semiquantitative reverse transcriptase (RT)-PCR method as we described previously. 16 
Physiological Protocols
Indirect BP was monitored in nonanesthetized animals by a standard tail-cuff method. 16 -18 Direct BP was determined in free-moving animals as previously described. 16 -18 For vascular smooth muscle studies, 3-mm-long segments of rat renal resistance arterioles were used. 18, 23 Contractile responses to KCl, phenylephrine, and acetylcholine were evaluated as described previously. 18 [Ca 2ϩ ] i in dissociated renal resistance arterial cells in response to KCl and Ang II was measured exactly as we described previously. 23 Ca 2ϩ current recordings were carried out by voltage-clamping single cells. 23 
Pathophysiological Parameters
Heart weight-to-body weight ratio, cardiac fibrosis, and collagen volume in both endocardium and epicardium were determined by our previously published protocols. 18 Animals were killed and perfused with fixative without applying additional pressure, according to a previously published protocol. 24 Morphometric analysis of thoracic aorta to determine the wall thickness and media/lumen ratio was carried out by an established protocol. 24 
Statistics
Results are expressed as meanϮSE. Statistical significance was evaluated with repeated measures, ANOVA, and Student's t test for unpaired data. Differences were considered significant at PϽ0.05. For vascular studies, all rings were normalized to tissue weights and cross-sectional area.
Results
Five-day-old WKY rats and SHR were administered 1ϫ10 9 cfu of LNSV (control virus) or LNSV-AT 1 R-AS (LNSV virus containing AT 1 R-AS cDNA) via an intracardiac injection. Animals were allowed to grow and were subjected to routine indirect BP monitoring. Two sets of LNSV-treated WKY rats (mean BP 129Ϯ6.0 mm Hg) and SHR (mean BP 198Ϯ18 mm Hg) and LNSV-AT 1 R-AS-treated WKY and SHR (mean BP 120Ϯ6.0 and 153Ϯ9 mm Hg, respectively) were used as parents for breeding and an F 1 generation of rats was produced. Offspring from LNSV-AT 1 R-AS-treated SHR expressed significantly lower BP as early as 80 days of age compared with their LNSV-treated SHR control. By 120 days, the average BP of the AT 1 R-AS-treated SHR offspring was of 45Ϯ9 mm Hg lower than that observed in the LNSV-treated SHR offspring (150Ϯ10 versus 185Ϯ11 mm Hg, Figure 1 ). No significant effect on BP was observed between offspring of AT 1 R-AS-and LNSV-treated WKY rats. The LNSV-AT 1 R-AS-treated WKY rat group was not used further in our exper- Figure 1 . Effect of LNSV-AT 1 R-AS treatment on direct blood pressure in F 1 and F 2 SHR offspring. Five-day-old WKY and SHR were subjected to LNSV or LNSV-AT 1 R-AS treatment essentially as described previously. 16 -18 One hundred and twenty-day-old parents were bred to produce F 1 generation of offspring. Subsequently, 100-day-old F 1 generation was bred to generate F 2 generation offspring. At day 120 of age, rats were cannulated, and direct BP was measured. The number of animals for WKY and SHR parents was 16; for F 1 (nϭ12) and F 2 (nϭ10) offspring, the number of animals was 22. *Significantly different (PϽ0.02) from WKY rats. Significantly lower BP in LNSV-AT 1 R-AS-treated SHR parents and F 1 and F 2 offspring (PϽ0.005) compared with the LNSV-treated control SHR.
iment because the parents showed no effect on BP and cardiovascular and renal pathophysiology 18 and the BP of the offspring showed no change. The F 2 generation was produced by mating two pairs of F 1 SHR whose parents were treated at 5 days of age with LNSV alone or LNSV-AT 1 R-AS. As observed for the F 1 generation, the F 2 offspring derived from the original AT 1 R-AStreated SHR showed a significantly lower BP compared with F 2 offspring derived from LNSV-treated SHR controls. At 120 days of age, F 2 SHR derived from the AT 1 R-AS-treated rats had an average BP of 135Ϯ12 mm Hg versus 165Ϯ10 mm Hg in F 2 offspring from LNSV-treated SHR ( Figure 1 ). Genomic DNA from various tissues of LNSV-AT 1 R-AS-treated SHR parents and their F 1 and F 2 offspring was isolated. It was subjected to PCR to amplify LNSV-AT 1 R-AS and followed by the Southern analysis to detect the AT 1 R-AS gene incorporation. All of the tissues analyzed from the parents and both generations of offspring showed integration of LNSV-AT 1 R-AS (Figure 2A ). In addition, the expression of AT 1 R-AS in both parents and offspring was evident ( Figure 2B ).
The effect of losartan, an AT 1 receptor-specific antagonist and well-established antihypertensive drug, on offspring derived from AT 1 R-AS-treated SHR was also studied. Treatment of control SHR by losartan resulted in a 29Ϯ6 mm Hg decrease in BP (Figure 3) . A comparable decrease in BP was observed in LNSV-treated SHR. In contrast, no significant decrease in BP was observed in the LNSV-AT 1 R-AS-treated SHR. Similar to AT 1 R-AS-treated parents, their F 1 and F 2 offspring showed little lowering of BP by losartan whereas offspring from LNSV-treated parents experienced a 25 to 29 mm Hg decrease in BP (Figure 3 ). These observations confirm that the AT 1 R-AS treatment of parents produced antihypertensive effects in both parents and offspring through an AT 1 receptor-mediated mechanism and that the antihypertensive effect is as effective as the AT 1 receptor antagonist therapy. The conclusion that antisense gene therapy influences BP in the SHR by affecting the levels of AT 1 receptors is demonstrated by comparing the cardiac AT 1 receptors in the F 1 generation of LNSV-and AT 1 R-AS-treated SHR. Total numbers of AT 1 receptors (B max ) in the ventricles of the F 1 offspring derived from AT 1 R-AS-treated SHR were decreased by 36% compared with offspring from parents of LNSV-treated SHR (Table 1) .
Tissue remodeling and associated ultrastructural changes in tissues relevant to cardiovascular functions such as heart, kidney, and arteries are major contributing factors in the morbidity and mortality associated with hypertension. For example, left ventricular hypertrophy, a compensatory response of the heart to an increase in peripheral vascular resistance is an important pathophysiological manifestation of hypertension. We determined whether AT 1 R-AS treatment influences cardiac pathophysiology, and, if so, could this effect be maintained in their offspring. Heart weights of untreated SHR were 68% higher than those of WKY rats (Table 1) . AT 1 R-AS treatment significantly prevented this cardiac hypertrophy in parents. 18 Similarly, heart weights of the F 1 generation of AT 1 R-AS-treated SHR were 26% lower than the F 1 generation of LNSV-treated SHR (Table 1) . Cardiac hypertrophy was significantly prevented in the F 2 generation of AT 1 R-AS-treated SHR as well. Multifocal areas of fibrosis in the myocardium are another characteristic of hypertension in this model. Figure 4 provides an example 9 cfu of LNSV-AT 1 R-AS viral particles. Animals were allowed to grow for 120 days, and F 1 generation offspring was produced. F 2 offspring was generated by breeding 120-day-old F 1 parents. Genomic DNA was isolated and subjected to PCR with the use of a set of LNSV-specific primers that contained AT 1 R-AS (sense primer: 5Ј-GCC TCT GAG CTA TTC CAG AAG TAG-3Ј; antisense primer: 5Ј-GAG CCT GGA CCA CTG AT-3Ј). The resulting product was subjected to Southern blotting essentially as described. 38 (Figure 4c ) or in the control WKY rat (Figure 4a ). Collagen volume in both endocardium and epicardium, a measure of cardiac fibrosis, was Ͻ90% decreased in the offspring of LNSV-AT 1 R-AS SHR (Table 1) , confirming the morphological detection of fibrosis.
Ultrastructural examination of the thoracic aorta of the offspring of LNSV-AT 1 R-AS-treated SHR parents revealed a significant decrease in the wall and medial thickness compared with offspring of LNSV-treated SHR parents ( Table 1) . The lumen area was increased in this group of SHR offspring. For example, wall thickness in the SHR and LNSV-treated SHR offspring of F 2 generation was 36% to 90% greater than that of the WKY control. F 2 offspring from LNSV-AT 1 R-AStreated SHR demonstrated a 34% decrease in wall thickness, which was closer to values for the same measurement in WKY rats. Similarly, the media/lumen ratio was 42% lower in this generation of LNSV-AT 1 R-AS-treated SHR. These data clearly establish that AT 1 R-AS treatment prevents these vascular pathophysiological changes in this model of hypertension.
We examined the pathophysiological changes in the renal resistance arterioles and artery of the F 1 and F 2 offspring of AT 1 R-AS-treated SHR parents. The rationale was based on the fact that an increased vascular tone leading to an increased renal vascular resistance is an important underlying mechanism in the elevation of BP. 25, 26 The cellular mechanisms responsible for this include an enhanced contractile sensitivity to vasoactive agents, an impaired endothelial-dependent vasorelaxation, increased [Ca 2ϩ ] i by its transport across the vascular smooth muscle cell (VSMC) membrane, altered ion channel activity in VSMC, and smooth muscle cell hypertrophy and hyperplasia. 23 We examined the effect of parental treatment of AT 1 R-AS of the SHR on the above pathophysiological parameters in the renal resistance arteriole and renal artery in the F 1 and F 2 offspring. Ultrastructural examination revealed that the thickness of the intima and media and the overall arterial morphological changes characteristic of hypertension were prevented in the SHR offspring of AT 1 R-AS-treated parents (Figure 4d through 4f) . Next, we examined the effects of AT 1 R-AS treatment on renal vascular reactivity. Our previous studies have shown that the SHR renal arteriole expresses an enhanced contractile response to KCl and phenylephrine. This enhancement, a result of a leftward shift of the concentration-response curve reflecting in the EC 50 for KCl and phenylephrine, was attenuated in AT 1 R-AS-treated SHR. 18 In the present study, the renal vascular response in offspring of both F 1 and F 2 generations of parents treated with LNSV-AT 1 R-AS was examined. In the parents, the vascular contractile responses to KCl and phenylephrine were shifted rightward as a result of an increase in EC 50 values in both F 1 and F 2 generation of offspring from LNSV-AT 1 R-AS-treated SHR. Data for the F 2 generation are presented in Table 2 as an example. As a result, the EC 50 values for F 1 and F 2 generations from the LNSV-AT 1 R-AS-treated SHR parents were comparable to those in the WKY rat. In contrast to the result with KCl and phenylephrine when compared with WKY, the untreated and LNSV-treated SHR showed a shift to the right in the acetylcholine-induced vasorelaxation of precontracted renal arteriole as reflected by an increase in the EC 50 as well as a decrease in the maximal effect. This effect was significantly improved in the offspring of parents treated with LNSV-AT 1 R-AS. For example, the EC 50 response of F 2 offspring of 23 †Data are meanϮSE, nϭ12. ‡AT 1 receptor B max was determined essentially as described previously.
14,15 F 1 generation offspring were used for 125 I-Sar 1 Ile 8 -Ang II binding experiments. Data are meanϮSE (nϭ3). §Morphometric data were collected and analyzed as described previously from the F 2 generation of offspring. 24 
Data are meanϮSE (nϭ3).
Values are significantly different (PϽ0.01) from the LNSV-SHR and SHR. ¶Values are significantly different (PϽ0.05, nϭ3) from the LNSV-SHR. NA indicates not analyzed.
LNSV-AT 1 R-AS-treated SHR was 77% lower when compared with the LNSV-treated SHR and was similar to that of the WKY rat. Similarly, the efficacy was 2.2-fold higher and comparable to the WKY rat (Table 2 ). These data demonstrate that endothelial dysfunction associated with hypertension is prevented by AT 1 R-AS gene therapy on a permanent basis.
We also studied L-type Ca 2ϩ current in F 1 and F 2 generations from LNSV-and LNSV-AT 1 R-AS-treated SHR parents. The rationale for this experiment was based on our previous observations that demonstrated that L-type Ca 2ϩ current is increased in VSMCs of the renal arterioles of the SHR. 23 Ca 2ϩ current was significantly decreased in both F 1 and F 2 generations of LNSV-AT 1 R-AS-treated SHR parents compared with that from the LNSV-treated SHR parent. The mean I-V relationship demonstrating this conclusion is presented in Figure 5A for the F 2 generation of offspring. Differences in the peak Ca 2ϩ current are shown in Table 2 . , and LNSV-AT 1 R-AS-treated SHR (c) parents were used to determine fibrosis essentially as described elsewhere. 18 Barϭ12 mm. Arrows show multifocal areas of fibrosis. F 2 rats were killed, and renal arteries were dissected from the main aorta and fixed in 3% paraformaldehyde. 24 Sections from 3 mm distal from the aorta were compared in WKY (d), LNSV-treated SHR (e), and LNSV-AT 1 R-AS-treated SHR parents (f). Barϭ1 mm. Figure 5B show that KCl-or Ang II-induced [Ca 2ϩ ] i increases in F 1 offspring from LNSV-AT 1 R-AStreated SHR parents were significantly attenuated when compared with the KCl and Ang II responses in the offspring from LNSV-treated SHR parents. Similar data were obtained in the F 2 generation. These findings provide additional evidence that alterations in the [Ca 2ϩ ] i homeostasis by the SHR renal arteriolar cells are permanently prevented by AT 1 R-AS gene therapy.
Discussion
The observations presented in this study demonstrate that a single intracardial administration of a retroviral vector containing AT 1 R-AS causes a permanent protection against hypertension in this animal model of human primary hypertension. Thus, it suggests that an antisense strategy to inhibit the RAS at a genetic level is a conceptually novel approach for the prevention of hypertension. The reduction in BP is associated with the prevention of hypertension-associated pathophysiological and ultrastructural changes in the renal and cardiac tissue. In addition, this cardiovascular protection against hypertension is transmitted to at least two subsequent generations.
The most important question that arises from the study concerns the mechanism of by which normotensive phenotypes are transmitted from parents to offspring. Our data in Figure 2 support the notion that the AT 1 R-AS is integrated into the parental genome and is transmitted to the offspring. The proposed germ-line transmission of the AT 1 R-AS is consistent with previous reports demonstrating the integration of retroviral vector and its germ-line transmission in other systems. [27] [28] [29] However, this study is unique because it shows that the transmission and accompanied expression of the AT 1 R-AS is associated with profound antihypertensive physiological changes in the offspring. Although we know little about the efficiency of this transduction, it must be high enough to influence the expression of antihypertensive phenotypes, an end point that is of ultimate relevance to hypertension. The possibility that lack of a blood-gonadal barrier and the presence of significant numbers of undifferentiated germ cells in the neonatal rat cannot be ruled out. Thus, a critical age of the rat at which the viral administration was carried out may be the key for such a high efficiency of transduction in the offspring.
In spite of our evidence in favor of AT 1 R-AS transmission, other possibilities to explain this prolonged antihypertensive effect should not be ruled out at the present time. For example, studies have shown that parental environment is critical in the development of hypertension. 30 -32 Thus, it is quite possible that the exposure of an antihypertensive environment by the AT 1 R-AS treatment of parents induces normotensive phenotype in the offspring. Cross studies with the SHR would support this review. 32, 33 In addition, the possibility that the AT 1 R-AS expression at a critical stage of SHR development may irreversibly prevent the parents and offspring from developing hypertension. This would be consistent with previous suggestions. 34 Finally, it is also quite possible that a combination of these mechanisms may ultimately be responsible for such a dramatic protection against hypertension.
Finally, is antisense gene therapy that targets the RAS a therapeutic step forward? On the basis of our data, the answer has to be affirmative. In our model, a single injection of retroviral vector containing AT 1 R-AS offers permanent prevention of hypertension. It not only minimizes side effects but also resolves the compliance issue observed in traditional pharmacological therapy. However, caution must be taken in use of this vector for any long-term therapeutics because of some concern as to an unknown insertion site of the retroviral vector in the genome. Another caveat of this study is that its success depends on the identification of the genetic determinants of hypertension at the prehypertensive stage before the therapy can be considered for human use. Angiotensin I-converting enzyme (ACE) may be one such determinant. It is well-established that ACE gene polymorphism cosegregates with hypertension, 35, 36 and that mutations at key places in ACE are associated with the development of high BP. 37, 38 Thus, targeting ACE by such an antisense strategy may be important. Would gene therapy reverse hypertension in the adult animal? A pilot study demonstrates a relatively longterm reversal of high BP and other renal pathophysiological changes induced by hypertension in adult SHR. 39 In conclu- sion, our observation provides an initial step forward toward the use of gene therapy for a permanent benefit to the cardiovascular system in the control of hypertension.
